Dapagliflozin vs Empagliflozin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: SGLT2 · full Type 2 Diabetes pipeline
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca and partners
NCT00528372 · Phase 3 · completed
The study was randomized, double-blind, placebo-controlled, and included 1,067 enrolled participants, with 558 receiving short-term treatment; its primary HbA1c endpoint is an accepted disease-defining measure for type 2 diabetes. Results were mixed across the primary dose comparisons: 5 mg and 10 mg morning doses significantly outperformed placebo, while 2.5 mg did not, and the exploratory high-baseline-HbA1c group lacked a comparator.
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Adjusted Mean Change From Baseline in HbA1c Levels (Baseline to week 24): Dapagliflozin 10mg Plus Metformin Plus Sulfonylurea -0.86 Percent (95% CI -1 to -0.72) vs Placebo Plus Metformin Plus Sulfonylurea -0.17 Percent (95% CI -0.31 to -0.02) (met)
Result source: NCT01392677
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT01131676 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial enrolling 7,064 participants. The hard clinical primary endpoint was met: pooled empagliflozin was non-inferior and also statistically superior to placebo for 3-point MACE, with 10.5% versus 12.1% of participants experiencing an event (HR 0.86; p=0.0382).
Next expected readout: November 2026 · NCT05057806 (registry estimate)
Reported efficacy
Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Time to the First Occurrence of Any of the Following Adjudicated Components of the Primary Composite Endpoint (3-point MACE): CV Death (Including Fatal Stroke and Fatal MI), Non-fatal MI (Excluding Silent MI), and Non-fatal Stroke. (From randomisation to individual end of observation, up to 4.6 years): Empagliflozin 10 mg 10.4% | Empagliflozin 25 mg 10.5% | All Empagliflozin 10.5% vs Placebo 12.1% (met)
Result source: NCT01131676
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dapagliflozin | Empagliflozin |
|---|---|---|
| HbA1c, change | -0.9% vs -0.2%−0.7 vs placeboNCT0052837250 other results
| -0.7% vs -0.2%−0.5 vs placeboNCT0115960032 other results
|
| Body weight, change (kg) | -3.2 vs -2.2−1 vs placeboNCT0052837240 other results
| -2.1 vs -0.4−1.7 vs placeboNCT0115960018 other results
|
| HbA1c below 7% | 50.8% vs 31.6%+19.2 vs placeboNCT0052837217 other results
| 34.6% vs 24.5%+10.1 vs placeboNCT034295433 other results
|
| Fasting plasma glucose, change | -1.3 vs 0.2−1.5 vs placeboNCT0098486734 other results
| -1.8 vs 0.3−2.1 vs placeboNCT0173478511 other results
|
| 3-point MACE (% with event) | —Not posted · NCT04170998 | 10.4% vs 12.1%−1.7 vs placeboNCT011316762 other results
|
HbA1c, change
- Dapagliflozin
- -0.9% vs -0.2%−0.7 vs placeboNCT00528372
50 other results
- -0.8% vs -0.2% NCT00528372
- -0.9% vs -0.2% NCT01392677
- -0.9% vs -0.3% NCT00673231
- -0.8% vs -0.3% NCT00673231
- -0.8% vs -0.3% NCT00673231
- -0.6% vs 0.1% NCT00357370
- -0.7% vs 0.1% NCT00357370
- -0.8% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.6% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.8% vs -0.3% NCT00528879
- -0.8% vs -0.1% NCT00680745
- -1.0% vs -0.4% NCT00683878
- -0.7% vs -0.3% NCT00528879
- -0.6% vs -0.1% NCT00680745
- -0.8% vs -0.4% NCT00683878
- -0.7% vs -0.3% NCT00528879
- -0.6% vs -0.1% NCT00680745
- -0.6% vs 0.4% NCT03199053
- -0.5% vs 0.0% NCT00984867
- -1.2% vs -1.4% NCT00643851
- -2.0% vs -1.4% NCT00643851
- -0.5% vs -0.5% NCT00660907
- -2.0% vs -1.4% NCT00859898
- -1.4% vs -1.4% NCT00859898
- -0.9% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.7% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.6% vs -0.2% NCT00528372
- -0.8% vs -0.2% NCT00528372
- -0.9% vs -0.3% NCT00528879
- -0.7% vs -0.3% NCT00528879
- -0.7% vs -0.3% NCT00528879
- -2.0% vs 0.2% NCT00528372
- -1.2% vs 0.2% NCT00528372
- -1.4% vs -0.5% NCT00528879
- -0.8% vs 0.0% NCT00984867
- -2% vs 0.2% NCT00528372
- -1.5% vs 0.2% NCT00528372
- -1.3% vs 0.2% NCT00528372
- -1.4% vs 0.2% NCT00528372
- -1.3% vs -0.5% NCT00528879
- -1.2% vs -0.5% NCT00528879
- -1.7% vs -1.8% NCT00643851
- -3.0% vs -1.8% NCT00643851
- -2.6% vs -2.0% NCT00859898
- -2.1% vs -2.0% NCT00859898
- -1% vs -0.5% NCT02564926
- Empagliflozin
- -0.7% vs -0.2%−0.5 vs placeboNCT01159600
32 other results
- -0.8% vs -0.2% NCT01159600
- -0.8% vs -0.2% NCT01159600
- -0.8% vs -0.2% NCT01159600
- -1.1% vs -0.1% NCT04233801
- -0.7% vs 0.1% NCT02182830
- -2.8% vs -0.2% NCT01159600
- -2.5% vs -0.2% NCT01159600
- -1.1% vs -0.1% NCT04233801
- -0.9% vs -0.3% NCT02489968
- -0.6% vs 0.1% NCT01734785
- -0.9% vs -0.3% NCT02489968
- -0.9% vs 0.2% NCT02453555
- -0.7% vs 0.1% NCT01734785
- -1.4% vs -1.8% NCT01719003
- -2.1% vs -1.8% NCT01719003
- -0.2% vs 0.3% NCT03429543
- -1.4% vs -1.8% NCT01719003
- -1.9% vs -1.8% NCT01719003
- -2.1% vs -1.8% NCT01719003
- -2.0% vs -1.8% NCT01719003
- -0.5% vs 0.3% NCT03429543
- 0.1% vs 0.3% NCT03429543
- -1.1% vs 0.1% NCT02453555
- -1.1% vs -0.0% NCT02453555
- -0.2% vs 0.1% NCT03429543
- -0.6% vs -0.2% NCT01649297
- -0.7% vs -0.2% NCT01649297
- -0.8% vs -0.2% NCT01649297
- -0.7% vs -0.1% NCT04531462
- -0.9% vs 0% NCT02589639
- -1% vs 0% NCT02589639
- -0.7% vs -0.2% NCT01649297
Body weight, change (kg)
- Dapagliflozin
- -3.2 vs -2.2−1 vs placeboNCT00528372
40 other results
- -3.0 vs -2.2 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -2.6 vs -0.6 NCT01392677
- -1.7 vs 0.0 NCT00673231
- -1.0 vs 0.0 NCT00673231
- -1.0 vs 0.0 NCT00673231
- -2.8 vs -2.2 NCT00528372
- -3.5 vs -2.2 NCT00528372
- -2.9 vs -2.4 NCT00528372
- -3.7 vs -2.4 NCT00528372
- -3.3 vs -2.2 NCT00528372
- -3.8 vs -2.2 NCT00528372
- -3.4 vs -2.4 NCT00528372
- -4.3 vs -2.4 NCT00528372
- -2.9 vs -0.9 NCT00528879
- -3.1 vs -1.0 NCT00528879
- -2.3 vs -0.7 NCT00680745
- -2.5 vs -0.8 NCT00680745
- -0.1 vs 1.6 NCT00683878
- -0.1 vs 1.8 NCT00683878
- -3.0 vs -0.9 NCT00528879
- -3.2 vs -1.0 NCT00528879
- -1.6 vs -0.7 NCT00680745
- -1.7 vs -0.8 NCT00680745
- 0.1 vs 1.6 NCT00683878
- 0.3 vs 1.8 NCT00683878
- -2.2 vs -0.9 NCT00528879
- -2.4 vs -1.0 NCT00528879
- -1.2 vs -0.7 NCT00680745
- -1.2 vs -0.8 NCT00680745
- -2.1 vs -0.3 NCT00984867
- -2.6 vs -1.3 NCT00643851
- -2.9 vs -1.5 NCT00643851
- -2.7 vs -1.3 NCT00643851
- -3.0 vs -1.5 NCT00643851
- -3.3 vs -1.4 NCT00859898
- -2.7 vs -1.4 NCT00859898
- -3.2 vs 1.4 NCT00660907
- -2.4 vs 1.3 NCT02564926
- Empagliflozin
- -2.1 vs -0.4−1.7 vs placeboNCT01159600
18 other results
- -2.2 vs -0.4 NCT01159600
- -2.0 vs 0.0 NCT04233801
- -2.2 vs -1.0 NCT02182830
- -2.5 vs -0.4 NCT01159600
- -2.4 vs -0.4 NCT01159600
- -0.8 vs -0.0 NCT03429543
- -1.3 vs -0.4 NCT01159600
- -1.3 vs -0.4 NCT01159600
- -1.3 vs 0.0 NCT04233801
- -2.5 vs -0.3 NCT01734785
- -3.1 vs -0.3 NCT01734785
- 1.3 vs -0.0 NCT03429543
- -2.4 vs -1.3 NCT01719003
- -2.4 vs -1.3 NCT01719003
- -3.8 vs -1.3 NCT01719003
- -3.0 vs -1.3 NCT01719003
- -3.5 vs -1.3 NCT01719003
- -2.8 vs -1.3 NCT01719003
HbA1c below 7%
- Dapagliflozin
- 50.8% vs 31.6%+19.2 vs placeboNCT00528372
17 other results
- 51.6% vs 31.6% NCT00528372
- 31.8% vs 11.1% NCT01392677
- 44.2% vs 31.6% NCT00528372
- 44% vs 31.6% NCT00528372
- 41.3% vs 31.6% NCT00528372
- 51.4% vs 31.6% NCT00528372
- 40.6% vs 25.9% NCT00528879
- 31.7% vs 13% NCT00680745
- 38.8% vs 22.4% NCT00683878
- 37.5% vs 25.9% NCT00528879
- 30.3% vs 13% NCT00680745
- 32.5% vs 22.4% NCT00683878
- 33% vs 25.9% NCT00528879
- 26.8% vs 13% NCT00680745
- 26.6% vs 10% NCT03199053
- 22.5% vs 34.6% NCT00643851
- 52.4% vs 34.6% NCT00643851
- Empagliflozin
- 34.6% vs 24.5%+10.1 vs placeboNCT03429543
3 other results
- 16.7% vs 8.2% NCT04233801
- 30.1% vs 8.2% NCT04233801
- 66.7% vs 24.5% NCT03429543
Fasting plasma glucose, change
- Dapagliflozin
- -1.3 vs 0.2−1.5 vs placeboNCT00984867
34 other results
- -1.6 vs -0.2 NCT00528372
- -1.6 vs -0.2 NCT00528372
- -1.9 vs -0.0 NCT01392677
- -1.2 vs 0.2 NCT00673231
- -1.0 vs 0.2 NCT00673231
- 0.1 vs 1.0 NCT00357370
- -0.9 vs -0.1 NCT00528372
- -0.7 vs 0.2 NCT00673231
- -1.1 vs -0.1 NCT00528372
- -0.5 vs 1.0 NCT00357370
- -1.3 vs -0.2 NCT00528372
- -1.5 vs -0.2 NCT00528372
- -0.9 vs -0.1 NCT00528372
- -1.0 vs -0.1 NCT00528372
- -0.8 vs -0.2 NCT00528372
- -1.4 vs -0.2 NCT00528372
- -0.2 vs -0.1 NCT00528372
- -1.6 vs -0.1 NCT00680745
- -0.8 vs -0.1 NCT00528372
- -1.3 vs -0.3 NCT00528879
- -1.6 vs -0.3 NCT00683878
- -0.9 vs 0.1 NCT00528879
- -1.2 vs -0.3 NCT00528879
- -1.2 vs -0.1 NCT00680745
- -1.4 vs -0.3 NCT00683878
- -0.7 vs 0.1 NCT00528879
- -1.0 vs -0.3 NCT00528879
- -0.9 vs -0.1 NCT00680745
- -0.3 vs 0.1 NCT00528879
- -0.6 vs 0.5 NCT03199053
- -2.3 vs -1.9 NCT00643851
- -3.4 vs -1.9 NCT00643851
- -3.4 vs -1.9 NCT00859898
- -2.6 vs -1.9 NCT00859898
- Empagliflozin
- -1.8 vs 0.3−2.1 vs placeboNCT01734785
11 other results
- -1.5 vs 0.3 NCT01734785
- -1.8 vs -1.8 NCT01719003
- -1.6 vs -1.8 NCT01719003
- -2.8 vs -1.8 NCT01719003
- -2.4 vs -1.8 NCT01719003
- -2.6 vs -1.8 NCT01719003
- -2.5 vs -1.8 NCT01719003
- -1.0 vs -0.0 NCT01649297
- -1.3 vs -0.0 NCT01649297
- -1.5 vs -0.0 NCT01649297
- -1.2 vs -0.0 NCT01649297
3-point MACE (% with event)
- Dapagliflozin
- —Not posted · NCT04170998
- Empagliflozin
- 10.4% vs 12.1%−1.7 vs placeboNCT01131676
2 other results
- 10.5% vs 12.1% NCT01131676
- 10.5% vs 12.1% NCT01131676
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Dapagliflozin: 9 of 9 rows · Empagliflozin: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dapagliflozin Rows use multiple source trials | Empagliflozin Rows use multiple source trials |
|---|---|---|
| DBP absolute change · mmHg | -0.25 vs 2.36 Glimepiride mmHg @ 52wka,b,c,d NCT02564926 · Phase 4 · registry result, not featured evidence | -3.37 vs -1.59 placebo mmHg @ 24wk10 mge,a,b,c,d NCT04233801 · Phase 3 · registry result, not featured evidence show 1 more dose-0.94 vs -1.59 placebo mmHg @ 24wk25 mg NCT04233801 · Phase 3 · registry result, not featured evidence |
| HbA1c absolute change · percentage points No placebo or comparator arm | -0.74% (n=19) @ 26wk10 mge,f,b,c,g NCT03199053 · Phase 3 show 1 more dose-0.71% (n=21) @ 26wk5 mg NCT03199053 · Phase 3 | -0.55% (n=32) @ 52wk10 mge,f,b,c,g NCT02589626 · Phase 4 · registry result, not featured evidence show 1 more dose-0.77% (n=33) @ 52wk25 mg NCT02589626 · Phase 4 · registry result, not featured evidence |
| Lean Mass absolute change · kg | -1.1 vs 0.2 Glimepiride kg @ 52wkb,c NCT02564926 · Phase 4 · registry result, not featured evidence | -1.61 vs -1.08 placebo kg @ 52wk10 mgb,c NCT04531462 · Phase 4 · registry result, not featured evidence |
| SBP absolute change · mmHg | -2.18 vs 4.63 Glimepiride mmHg @ 52wka,b,c,d NCT02564926 · Phase 4 · registry result, not featured evidence | -5.56 vs -1.95 placebo mmHg @ 24wk10 mge,a,b,c,d NCT04233801 · Phase 3 · registry result, not featured evidence show 1 more dose-2.96 vs -1.95 placebo mmHg @ 24wk25 mg NCT04233801 · Phase 3 · registry result, not featured evidence |
| Seated SBP absolute change · mmHg | -4.04 vs -0.27 placebo mmHg @ 8wk10 mgh,i,j NCT01392677 · Phase 3 · combination 1 other source trial-5.98 vs -5.12 placebo mmHg @ 8wk NCT00984867 · Phase 3 | -0.12 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mge,h,i,j NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 show 1 more dose2.63 vs 1.3 placebo mmHg @ 26wk10 mg, 25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 |
| Dropout rate | 18.6%10 mg AMk NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results14.5%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 12.8%10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 18.8%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 16.2%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.6%5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 7.7%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 13.4%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 0%20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 14.2%Dapagliflozin NCT00859898 · Phase 3 13.3%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 16.3%5 mg NCT00643851 · Phase 3 8.8%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 11.9%10 mg NCT00528879 · Phase 3 · combination 10.9%5 mg NCT00528879 · Phase 3 · combination —5.0 mg NCT00528879 · Phase 3 · combination 12.4%2.5 mg NCT00528879 · Phase 3 · combination 20.7% NCT00660907 · Phase 3 · combination 6.6%10 mg NCT00680745 · Phase 3 · combination 9%5 mg NCT00680745 · Phase 3 · combination 9.1%2.5 mg NCT00680745 · Phase 3 · combination 7.3%10 mg NCT01392677 · Phase 3 · combination 10%10MG NCT00683878 · Phase 3 · combination 11.3%5MG NCT00683878 · Phase 3 · combination 7.6% NCT00984867 · Phase 3 9.2%10mg NCT00673231 · Phase 3 12.3%5mg NCT00673231 · Phase 3 10.9%2.5mg NCT00673231 · Phase 3 2.5%10mg QD NCT02413398 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 · combination —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 6.2%Dapagliflozin NCT03199053 · Phase 3 · background therapy 1.3%10 mg NCT01730534 · Phase 3 16.7%Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence 16.7%Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence 0%T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence 0%Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence 0%Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination 12.9% NCT03782259 · Phase 4 · registry result, not featured evidence 16% NCT02235298 · Phase 4 · registry result, not featured evidence — NCT02796170 · Phase 4 · registry result, not featured evidence —10mg NCT03338855 · Phase 4 · registry result, not featured evidence — NCT02973477 · Phase 4 · registry result, not featured evidence 7.4%10 mg NCT03387683 · Phase 4 · registry result, not featured evidence 7.7% NCT02433678 · Phase 4 · registry result, not featured evidence 0%10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence 8.3% NCT03074630 · Phase 4 · registry result, not featured evidence 13.3% NCT02564926 · Phase 4 · registry result, not featured evidence | 23.7%10 mgl NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results23.2%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 8%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.7%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 8.7%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 17.5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 8.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 15.9%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 —10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 6.2%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 11.2%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 4.4%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 9.4%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence 6.1%25 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25mg NCT02589626 · Phase 4 · registry result, not featured evidence 2.7%10 mg NCT04233801 · Phase 3 · registry result, not featured evidence 5.5%25 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 18.1%10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 7%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 10.2%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 7.5%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5.3%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 10%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 9.9%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 7.7%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT01947855 · Phase 3 · registry result, not featured evidence 0%25 mg NCT01947855 · Phase 3 · registry result, not featured evidence —Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 8.6%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 6%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 6.4%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 7.8%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 8.6%10 mg AMk NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results3.9%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.1%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 4.4%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.1%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 —20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 4.1%Dapagliflozin NCT00859898 · Phase 3 1.9%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 3%5 mg NCT00643851 · Phase 3 1%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 3%10 mg NCT00528879 · Phase 3 · combination 1.5%5 mg NCT00528879 · Phase 3 · combination —5.0 mg NCT00528879 · Phase 3 · combination 2.9%2.5 mg NCT00528879 · Phase 3 · combination 8.1% NCT00660907 · Phase 3 · combination 2%10 mg NCT00680745 · Phase 3 · combination 2.1%5 mg NCT00680745 · Phase 3 · combination 3.2%2.5 mg NCT00680745 · Phase 3 · combination 0.9%10 mg NCT01392677 · Phase 3 · combination 2.1%10MG NCT00683878 · Phase 3 · combination 2.1%5MG NCT00683878 · Phase 3 · combination 3.1% NCT00984867 · Phase 3 3.1%10mg NCT00673231 · Phase 3 4.2%5mg NCT00673231 · Phase 3 2.5%2.5mg NCT00673231 · Phase 3 —10mg QD NCT02413398 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 —10 mg NCT03199053 · Phase 3 · combination —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —5 mg NCT03199053 · Phase 3 —Dapagliflozin NCT03199053 · Phase 3 · background therapy —10 mg NCT01730534 · Phase 3 —Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence —Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence —Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence —T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence —Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence —Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination — NCT03782259 · Phase 4 · registry result, not featured evidence 4% NCT02235298 · Phase 4 · registry result, not featured evidence — NCT02796170 · Phase 4 · registry result, not featured evidence —10mg NCT03338855 · Phase 4 · registry result, not featured evidence — NCT02973477 · Phase 4 · registry result, not featured evidence —10 mg NCT03387683 · Phase 4 · registry result, not featured evidence — NCT02433678 · Phase 4 · registry result, not featured evidence —10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence — NCT03074630 · Phase 4 · registry result, not featured evidence — NCT02564926 · Phase 4 · registry result, not featured evidence | 11.4%10 mgl NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results11.6%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 2.7%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 0.9%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 3.2%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 4.9%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.3%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 1.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 —10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 4.6%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 5.6%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 3.3%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 3.1%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence 3%25 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25mg NCT02589626 · Phase 4 · registry result, not featured evidence —10 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg NCT04233801 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination —10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence —25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination —10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 1.7%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 2.4%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 0%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 3.5%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 2.9%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 2.3%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination —10 mg NCT01947855 · Phase 3 · registry result, not featured evidence —25 mg NCT01947855 · Phase 3 · registry result, not featured evidence —Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 5.9%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 1.8%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 1.4%10 mg AMk NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 53 more results3.9%10 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —10 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 6.3%5 mg AM NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 7.4%5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 —5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 9.2%2.5 mg AM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 10.4%2.5 mg PM NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 0%10 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 4.2%20 mg NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 2.3%Dapagliflozin NCT00859898 · Phase 3 1.4%Dapagliflozin + Metformin XR NCT00859898 · Phase 3 · combination 4.4%5 mg NCT00643851 · Phase 3 3.1%Dapagliflozin 5 mg + Metformin XR NCT00643851 · Phase 3 · combination 10.4%10 mg NCT00528879 · Phase 3 · combination —5 mg NCT00528879 · Phase 3 · combination 6.6%5.0 mg NCT00528879 · Phase 3 · combination 10.9%2.5 mg NCT00528879 · Phase 3 · combination 8.6% NCT00660907 · Phase 3 · combination 6%10 mg NCT00680745 · Phase 3 · combination 6.9%5 mg NCT00680745 · Phase 3 · combination 7.1%2.5 mg NCT00680745 · Phase 3 · combination 0.9%10 mg NCT01392677 · Phase 3 · combination 1.4%10MG NCT00683878 · Phase 3 · combination 2.8%5MG NCT00683878 · Phase 3 · combination 4.4% NCT00984867 · Phase 3 7.1%10mg NCT00673231 · Phase 3 4.7%5mg NCT00673231 · Phase 3 7.4%2.5mg NCT00673231 · Phase 3 5.6%10mg QD NCT02413398 · Phase 3 0%10 mg NCT03199053 · Phase 3 4.8%10 mg NCT03199053 · Phase 3 0%10 mg NCT03199053 · Phase 3 · combination 1.2%5 mg NCT03199053 · Phase 3 0%5 mg NCT03199053 · Phase 3 9.1%5 mg NCT03199053 · Phase 3 —Dapagliflozin NCT03199053 · Phase 3 · background therapy 37.4%10 mg NCT01730534 · Phase 3 0%Dapagliflozin/Hyperfiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Dapagliflozin/Normofiltration NCT02911792 · Phase 4 · registry result, not featured evidence 0%Normal Glucose Tolerance (NGT) on NCT02981966 · Phase 4 · registry result, not featured evidence 0%T2DM Individuals on Dapagliflozin NCT02981966 · Phase 4 · registry result, not featured evidence 0%Byetta / Bydureon NCT02981069 · Phase 4 · registry result, not featured evidence 0%Byetta/Bydureon Plus Dapagliflozin NCT02981069 · Phase 4 · registry result, not featured evidence · combination — NCT03782259 · Phase 4 · registry result, not featured evidence 0% NCT02235298 · Phase 4 · registry result, not featured evidence 0% NCT02796170 · Phase 4 · registry result, not featured evidence 0%10mg NCT03338855 · Phase 4 · registry result, not featured evidence 2.3% NCT02973477 · Phase 4 · registry result, not featured evidence 0%10 mg NCT03387683 · Phase 4 · registry result, not featured evidence 0% NCT02433678 · Phase 4 · registry result, not featured evidence 0%10mg Once Daily NCT02682563 · Phase 4 · registry result, not featured evidence — NCT03074630 · Phase 4 · registry result, not featured evidence 10% NCT02564926 · Phase 4 · registry result, not featured evidence | 37.4%10 mgl NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 40 more results39%25 mg NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 4.9%10mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 3.2%10mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 0.5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 5%25mg NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.3%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 1.4%25mg NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 5.4%10 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 0%25 mg NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 —10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 12.3%10 mg NCT04531462 · Phase 4 · registry result, not featured evidence 10.5%10 mg NCT02589639 · Phase 4 · registry result, not featured evidence 8.9%25 mg NCT02589639 · Phase 4 · registry result, not featured evidence 6.3%10 mg NCT02589626 · Phase 4 · registry result, not featured evidence —25 mg NCT02589626 · Phase 4 · registry result, not featured evidence 3%25mg NCT02589626 · Phase 4 · registry result, not featured evidence 13.7%10 mg NCT04233801 · Phase 3 · registry result, not featured evidence 9.6%25 mg NCT04233801 · Phase 3 · registry result, not featured evidence 5.2%25 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 0.9%10 mg + 5 mg NCT02489968 · Phase 3 · registry result, not featured evidence · combination 3.7%10 mg-25 mg NCT02182830 · Phase 3 · registry result, not featured evidence 3.6%25 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 4.5%10 mg + 5 mg NCT01734785 · Phase 3 · registry result, not featured evidence · combination 0.6%10 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 1.8%25 mg qd NCT01719003 · Phase 3 · registry result, not featured evidence 3.8%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.2%12.5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 3.5%12.5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.8%5 mg Bid + 1000 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 1.2%5 mg Bid + 500 mg Bid NCT01719003 · Phase 3 · registry result, not featured evidence · combination 0%10 mg NCT01947855 · Phase 3 · registry result, not featured evidence 0%25 mg NCT01947855 · Phase 3 · registry result, not featured evidence 6.4%Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence 7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 0%25 mg NCT02632747 · Phase 2 · registry result, not featured evidence 2.3%10 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 0.9%25 mg QD NCT01649297 · Phase 2 · registry result, not featured evidence 2.3%12.5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence 3.2%5 mg BID NCT01649297 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mg AMk nasopharyngitis 14.3% (placebo 9.3%) arthralgia 8.6% (placebo 4%) headache 8.6% (placebo 12%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 show 42 more results10 mg PM headache 13.2% (placebo 12%) upper respiratory tract infection 11.8% (placebo 5.3%) back pain 9.2% (placebo 6.7%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 5 mg AM pharyngitis 9.4% (placebo 8%) arthralgia 7.8% (placebo 4%) headache 7.8% (placebo 12%) NCT00528372 · Phase 3 · Type 2 Diabetes · phase 3 5 mg PM headache 16.2% (placebo 12%) nasopharyngitis 13.2% (placebo 9.3%) arthralgia 11.8% (placebo 4%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg AM nasopharyngitis 16.9% (placebo 9.3%) influenza 10.8% (placebo 4%) arthralgia 9.2% (placebo 4%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 2.5 mg PM nasopharyngitis 16.4% (placebo 9.3%) abdominal pain 9% (placebo 2.7%) dizziness 9% (placebo 2.7%) NCT00528372 · Phase 3 · combination · Type 2 Diabetes · phase 3 10 mg back pain 12.5% (placebo 8.7%) headache 12.5% (placebo 8.7%) fatigue 8.3% (placebo 0%) NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 20 mg nausea 12.5% (placebo 4.3%) pollakiuria 12.5% (placebo 17.4%) vomiting 12.5% (placebo 0%) NCT00357370 · Phase 2/3 · monotherapy · Type 2 Diabetes · phase 2/3 diarrhoea 7.1% vulvovaginal mycotic infection 3.3% urinary tract infection 2.8% NCT00859898 · Phase 3 · combination 5 mg dyslipidaemia 5.4% upper respiratory tract infection 4.9% urinary tract infection 4.4% NCT00643851 · Phase 3 10 mg back pain 13.3% (placebo 8%) influenza 12.6% (placebo 10.9%) diarrhoea 11.9% (placebo 7.3%) NCT00528879 · Phase 3 · combination 5.0 mg influenza 14.6% (placebo 10.9%) headache 9.5% (placebo 5.8%) arthralgia 7.3% (placebo 5.1%) NCT00528879 · Phase 3 · combination 2.5 mg influenza 13.9% (placebo 10.9%) nasopharyngitis 11.7% (placebo 8.8%) back pain 8% (placebo 8%) NCT00528879 · Phase 3 · combination 10 mg hypoglycemia 7.9% (placebo 4.8%) nasopharyngitis 3.3% (placebo 2.7%) hypertension 1.3% (placebo 4.1%) NCT00680745 · Phase 3 · combination 5 mg hypoglycemia 6.9% (placebo 4.8%) nasopharyngitis 5.5% (placebo 2.7%) hypertension 1.4% (placebo 4.1%) NCT00680745 · Phase 3 · combination 2.5 mg hypoglycemia 7.1% (placebo 4.8%) hypertension 5.2% (placebo 4.1%) nasopharyngitis 1.9% (placebo 2.7%) NCT00680745 · Phase 3 · combination 10MG dyslipidaemia 9.3% (placebo 4.3%) nasopharyngitis 7.9% (placebo 3.6%) diarrhoea 6.4% (placebo 4.3%) NCT00683878 · Phase 3 · combination 5MG upper respiratory tract infection 6.4% (placebo 5.8%) dyslipidaemia 5.7% (placebo 4.3%) nasopharyngitis 5% (placebo 3.6%) NCT00683878 · Phase 3 · combination nasopharyngitis 4% (placebo 6.2%) NCT00984867 · Phase 3 10mg hypoglycemia 44.9% (placebo 42.1%) nasopharyngitis 8.7% (placebo 11.2%) urinary tract infection 5.6% (placebo 3%) NCT00673231 · Phase 3 5mg hypoglycemia 47.6% (placebo 42.1%) nasopharyngitis 13.7% (placebo 11.2%) hypertension 6.1% (placebo 8.1%) NCT00673231 · Phase 3 2.5mg hypoglycemia 55% (placebo 42.1%) nasopharyngitis 13.9% (placebo 11.2%) hypertension 5.4% (placebo 8.1%) NCT00673231 · Phase 3 10 mg abdominal pain 4.8% (placebo 2.6%) abdominal pain upper 4.8% (placebo 0%) bronchitis 4.8% (placebo 0%) NCT03199053 · Phase 3 10 mg dysmenorrhoea 9.5% (placebo 2.6%) headache 9.5% (placebo 1.3%) conjunctivitis allergic 4.8% (placebo 0%) NCT03199053 · Phase 3 10 mg pharyngotonsillitis 14.3% (placebo 1.3%) tonsillitis 14.3% (placebo 0%) abdominal pain 0% (placebo 2.6%) NCT03199053 · Phase 3 · combination 5 mg headache 7.4% (placebo 1.3%) hypertriglyceridaemia 4.9% (placebo 1.3%) diarrhoea 3.7% (placebo 3.9%) NCT03199053 · Phase 3 5 mg headache 9.1% (placebo 1.3%) nasopharyngitis 3.6% (placebo 2.6%) anxiety 1.8% (placebo 0%) NCT03199053 · Phase 3 5 mg influenza 5.5% (placebo 2.6%) abdominal pain upper 3.6% (placebo 0%) headache 3.6% (placebo 1.3%) NCT03199053 · Phase 3 10 mg renal impairment 1.4% (placebo 1.7%) acute kidney injury 1% (placebo 1.3%) chronic kidney disease 0.9% (placebo 1.2%) NCT01730534 · Phase 3 genital mycotic infection 13.3% mild hypoglycemia 0% NCT02911792 · Phase 4 · registry result, not featured evidence genital mycotic infection 26.7% mild hypoglycemia 0% NCT02911792 · Phase 4 · registry result, not featured evidence transcient syncope 12.5% (placebo 0%) NCT02981966 · Phase 4 · registry result, not featured evidence transcient syncope 0% (placebo 0%) NCT02981966 · Phase 4 · registry result, not featured evidence nausea and vomiting 24% (placebo 0%) genital mycosis 0% (placebo 0%) NCT02981069 · Phase 4 · registry result, not featured evidence nausea and vomiting 20% (placebo 0%) genital mycosis 8% (placebo 0%) NCT02981069 · Phase 4 · registry result, not featured evidence · combination dysuria 12% (placebo 0%) frequency of urination 12% (placebo 0%) balanitis 2% (placebo 0%) NCT02235298 · Phase 4 · registry result, not featured evidence cold like symptoms 4.5% genital yeast infection 4.5% abrasion of left cornea 2.3% NCT02973477 · Phase 4 · registry result, not featured evidence 10mg Once Daily genital fungal infections 20.8% NCT02682563 · Phase 4 · registry result, not featured evidence nasopharyngitis 6.7% toothache 6.7% hypoglycaemia 5% NCT02564926 · Phase 4 · registry result, not featured evidence | 10 mgl hypoglycaemia 29.6% (placebo 29.4%) urinary tract infection 14.5% (placebo 14.7%) hyperglycaemia 9.3% (placebo 18.1%) NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 show 37 more results25 mg hypoglycaemia 28.7% (placebo 29.4%) urinary tract infection 14.4% (placebo 14.7%) nasopharyngitis 9.4% (placebo 9.3%) NCT01131676 · Phase 3 · Type 2 Diabetes · phase 3 10mg hypoglycaemia 15.6% (placebo 9.8%) urinary tract infection 9.4% (placebo 6.7%) nasopharyngitis 8% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 10mg nasopharyngitis 5.5% (placebo 4.9%) urinary tract infection 4.1% (placebo 6.7%) hyperglycaemia 2.3% (placebo 12.4%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 25mg hypoglycaemia 12.9% (placebo 9.8%) urinary tract infection 6.9% (placebo 6.7%) nasopharyngitis 6% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 25mg hypoglycaemia 8.9% (placebo 9.8%) hyperglycaemia 7.9% (placebo 12.4%) nasopharyngitis 5% (placebo 4.9%) NCT01159600 · Phase 3 · combination · Type 2 Diabetes · phase 3 25mg nasopharyngitis 7% (placebo 4.9%) upper respiratory tract infections 4.2% (placebo 5.3%) urinary tract infection 4.2% (placebo 6.7%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 25mg nasopharyngitis 7.2% (placebo 4.9%) urinary tract infection 7.2% (placebo 6.7%) diarrhoea 5.8% (placebo 0%) NCT01159600 · Phase 3 · Type 2 Diabetes · phase 3 10 mg headache 16.2% (placebo 15.5%) hypoglycaemia 16.2% (placebo 12.1%) vitamin d deficiency 13.5% (placebo 13.8%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 25 mg hypoglycaemia 17.2% (placebo 12.1%) blood ketone body increased 10.3% (placebo 3.4%) headache 10.3% (placebo 15.5%) NCT03429543 · Phase 3 · pooled · Type 2 Diabetes · phase 3 10 mg constipation 10.8% (placebo 4.7%) pyrexia 6.2% (placebo 4.7%) nasopharyngitis 4.6% (placebo 6.3%) NCT04531462 · Phase 4 · registry result, not featured evidence 10 mg nasopharyngitis 34.9% (placebo 31.1%) hypoglycaemia 27.9% (placebo 21.1%) pollakiuria 10.5% (placebo 2.2%) NCT02589639 · Phase 4 · registry result, not featured evidence 25 mg hypoglycaemia 27.8% (placebo 21.1%) nasopharyngitis 26.7% (placebo 31.1%) pollakiuria 10% (placebo 2.2%) NCT02589639 · Phase 4 · registry result, not featured evidence 10 mg viral upper respiratory tract infection 31.3% fall 3.1% influenza 0% NCT02589626 · Phase 4 · registry result, not featured evidence 25mg viral upper respiratory tract infection 33.3% influenza 9.1% fall 6.1% NCT02589626 · Phase 4 · registry result, not featured evidence 10 mg hypoglycaemia 20.5% (placebo 15.1%) urinary tract infection 8.2% (placebo 13.7%) hyperlipidaemia 5.5% (placebo 2.7%) NCT04233801 · Phase 3 · registry result, not featured evidence 25 mg hypoglycaemia 15.1% (placebo 15.1%) urinary tract infection 8.2% (placebo 13.7%) hyperlipidaemia 5.5% (placebo 2.7%) NCT04233801 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg viral upper respiratory tract infection 26.7% (placebo 22.2%) blood ketone body increased 13.8% (placebo 10.2%) back pain 6% (placebo 2.8%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg viral upper respiratory tract infection 15% (placebo 22.2%) back pain 2.8% (placebo 2.8%) contusion 2.8% (placebo 0.9%) NCT02489968 · Phase 3 · registry result, not featured evidence · combination 10 mg-25 mg lipase increased 7.5% (placebo 3.9%) cough 6.3% (placebo 1.3%) upper respiratory tract infection 2.5% (placebo 5.2%) NCT02182830 · Phase 3 · registry result, not featured evidence 25 mg + 5 mg nasopharyngitis 3.6% (placebo 7.3%) lipase increased 2.7% (placebo 5.5%) urinary tract infection 2.7% (placebo 6.4%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg + 5 mg urinary tract infection 7.1% (placebo 6.4%) nasopharyngitis 4.5% (placebo 7.3%) lipase increased 3.6% (placebo 5.5%) NCT01734785 · Phase 3 · registry result, not featured evidence · combination 10 mg qd dyslipidaemia 8.7% urinary tract infection 7% upper respiratory tract infection 2.9% NCT01719003 · Phase 3 · registry result, not featured evidence 25 mg qd urinary tract infection 7.8% dyslipidaemia 6.6% upper respiratory tract infection 4.2% NCT01719003 · Phase 3 · registry result, not featured evidence 12.5 mg Bid + 1000 mg Bid diarrhoea 7.5% dizziness 5.7% gastritis 5.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 12.5 mg Bid + 1000 mg Bid urinary tract infection 10.6% diarrhoea 7.1% dyslipidaemia 4.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 12.5 mg Bid + 500 mg Bid urinary tract infection 10% dizziness 5.3% diarrhoea 3.5% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5 mg Bid + 1000 mg Bid urinary tract infection 7% dyslipidaemia 4.7% upper respiratory tract infection 4.7% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 5 mg Bid + 500 mg Bid dyslipidaemia 8.9% diarrhoea 5.3% urinary tract infection 5.3% NCT01719003 · Phase 3 · registry result, not featured evidence · combination 10 mg nasopharyngitis 10% (placebo 4.8%) anal inflammation 0% (placebo 0%) bartholinitis 0% (placebo 0%) NCT01947855 · Phase 3 · registry result, not featured evidence 25 mg anal inflammation 5.3% (placebo 0%) bartholinitis 5.3% (placebo 0%) pollakiuria 5.3% (placebo 0%) NCT01947855 · Phase 3 · registry result, not featured evidence nasopharyngitis 4.1% glomerular filtration rate decreased 3.8% hyperkalaemia 3.8% NCT05254002 · Phase 2 · registry result, not featured evidence hyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination 25 mg ketosis 19.4% (placebo 3.3%) fatigue 9.7% (placebo 0%) headache 9.7% (placebo 10%) NCT02632747 · Phase 2 · registry result, not featured evidence 10 mg QD urinary tract infection 6.8% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 25 mg QD urinary tract infection 4.6% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 12.5 mg BID urinary tract infection 4.6% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence 5 mg BID urinary tract infection 3.7% (placebo 3.7%) NCT01649297 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 52 weeks versus 24 weeks.
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fTrial phases differ: Phase 3 versus Phase 4.
- gAssessment timepoints differ: 26 weeks versus 52 weeks.
- hPopulation context differs: age eligibility differs (adolescents and adults versus includes children).
- iTreatment context differs: combination versus pooled.
- jAssessment timepoints differ: 8 weeks versus 26 weeks.
- kPopulation comparability has not been reviewed for 44 of these studies.
- lPopulation comparability has not been reviewed for 31 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapagliflozin
show 5 more results
show 1 more result
show 8 more results
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 1 more result
show 2 more results
show 2 more results
show 2 more results
+ 32 further endpoints in the CSV export.
Empagliflozin
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 2 more results
show 5 more results
show 3 more results
show 3 more results
+ 16 further endpoints in the CSV export.
Chronic Kidney Disease
Shared mechanism: SGLT2 · full Chronic Kidney Disease pipeline
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca and partners
NCT03036150 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of kidney failure and death, and dapagliflozin significantly reduced this composite compared with placebo.
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Time to the First Occurrence of Any of the Components of the Composite: ≥50% Sustained Decline in eGFR or Reaching ESRD or CV Death or Renal Death. (Up to 38.2 months): Primary composite outcome (sustained eGFR decline >=50%, end-stage kidney disease, or renal/cardiovascular death) at median 2.4 years: 9.2% (197/2152) with dapagliflozin vs 14.5% (312/2152) with placebo; hazard ratio 0.61 (95% CI 0.51-0.72), P<0.001 (met)
Result source: NCT03036150
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT03594110 · Phase 3 · completed
Patients with chronic kidney disease (6,609) were randomly assigned to empagliflozin 10 mg or matching placebo under double-blind conditions. The primary outcome was a composite of kidney disease progression or cardiovascular death. It was registered for the active trial and again for the whole study, which added up to 2 years of follow-up after the study drug stopped. Empagliflozin reduced the outcome in the active trial (hazard ratio 0.72, 95% CI 0.64 to 0.82, P<0.001) and over the whole study (hazard ratio 0.79, 95% CI 0.72 to 0.87). The figures come from the two published papers (N Engl J Med 2023 and 2025).
Next expected readout: December 2026 · NCT05786443 (registry estimate)
Reported efficacy
Time to first kidney disease progression or cardiovascular death (adjudicated): in the interventional part (up to 1136 days) and over the overall study including post-trial follow-up (up to 1869 days): Primary 1, kidney disease progression or cardiovascular death in the active trial (median 2.0 years): 432/3304 (13.1%) empagliflozin vs 558/3305 (16.9%) placebo; HR 0.72 (95% CI 0.64 to 0.82; P<0.001), met. Primary 2, the same outcome over the active trial plus post-trial follow-up: 865/3304 (26.2%) vs 1001/3305 (30.3%); HR 0.79 (95% CI 0.72 to 0.87), met. (met)
Result source: NCT03594110
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dapagliflozin | Empagliflozin |
|---|---|---|
| Kidney composite outcome | 6.6% vs 11.3%−4.7 vs placeboNCT03036150 | 6.1% vs 8.1%−2 vs placeboNCT035941101 other result
|
| UACR, % change | -22.4% vs -1.8%−20.6 vs placeboNCT025479359 other results
| -39.1% vs -2.6%−36.5 vs placeboNCT051828405 other results
|
| eGFR slope | —Not posted · NCT05998837 | —Not posted · NCT05373680 |
| Haemoglobin, change | —Not posted · NCT05998837 | —Not posted · NCT05373680 |
Kidney composite outcome
- Dapagliflozin
- 6.6% vs 11.3%−4.7 vs placeboNCT03036150
- Empagliflozin
- 6.1% vs 8.1%−2 vs placeboNCT03594110
1 other result
- 7.5% vs 8.9% NCT03594110
UACR, % change
- Dapagliflozin
- -22.4% vs -1.8%−20.6 vs placeboNCT02547935
9 other results
- -39.1% vs -1.8% NCT02547935
- -34.3% vs 230.3% NCT04595370
- -58.0% vs 230.3% NCT04595370
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- -34.3% vs 230.3% NCT04595370
- -58.0% vs 230.3% NCT04595370
- -42.1% vs 230.3% NCT04595370
- -56.4% vs 230.3% NCT04595370
- Empagliflozin
- -39.1% vs -2.6%−36.5 vs placeboNCT05182840
5 other results
- -36.6% vs -2.6% NCT05182840
- -22.4% vs -2.6% NCT05182840
- -19% vs -10.6% NCT05182840
- -45.9% vs -10.6% NCT05182840
- -40.3% vs -10.6% NCT05182840
eGFR slope
- Dapagliflozin
- —Not posted · NCT05998837
- Empagliflozin
- —Not posted · NCT05373680
Haemoglobin, change
- Dapagliflozin
- —Not posted · NCT05998837
- Empagliflozin
- —Not posted · NCT05373680
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Dapagliflozin: 8 of 8 rows · Empagliflozin: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dapagliflozin Rows use multiple source trials | Empagliflozin Rows use multiple source trials |
|---|---|---|
| Overall Survival time to event · count | 4.7% vs 6.8% placeboa,b,c NCT03036150 · Phase 3 | 0.1% vs 0.1% placebo10 mga,b,c NCT03594110 · Phase 3 |
| Time to Cardio-renal Composite Endpoint event count · % of participants | 9.2% (n=2152) vs 14.5% (n=2152) placebo*a,b,c NCT03036150 · Phase 3 · converted to % from 197 Participants as posted | 6.85% (n=3304) vs 8.96% (n=3305) placebo10 mgd,a,b,c NCT03594110 · Phase 3 show 1 more dose8.36% (n=3304) vs 9.99% (n=3305) placebo10 mg NCT03594110 · Phase 3 |
| UACR absolute change · mg | 0.48 vs 0.72 placebo mg @ 12wk1.5 mgd,a,e NCT04724837 · Phase 2 · registry result, not featured evidence · combination show 3 more doses0.48 vs 0.72 placebo mg @ 12wk1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 0.52 vs 0.72 placebo mg @ 12wk0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 0.52 vs 0.72 placebo mg @ 12wk0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination | -0.496 vs -0.027 placebo mg @ 14wk10 mgd,a,e NCT05182840 · Phase 2 · registry result, not featured evidence show 5 more doses-0.455 vs -0.027 placebo mg @ 14wk20 mg NCT05182840 · Phase 2 · registry result, not featured evidence -0.614 vs -0.112 Empagliflozin mg @ 14wk10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination -0.516 vs -0.112 Empagliflozin mg @ 14wk10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination -0.21 vs -0.112 Empagliflozin mg @ 14wk10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination -0.254 vs -0.027 placebo mg @ 14wk3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| UACR 30 responder rate · % of participants | 45% (n=144) vs 31.3% (n=148) placebo @ 24wk10 mgd,f,g,h NCT02547935 · Phase 2/3 · registry result, not featured evidence show 1 more dose57% (n=152) vs 31.3% (n=148) placebo @ 24wk10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination | 50.8% (n=61) vs 14.5% (n=69) placebo @ 14wk*10 mgd,f,g,h NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 31 Participants as posted show 23 more doses45.9% (n=61) vs 13% (n=69) placebo @ 14wk*10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted 50.8% (n=61) vs 20.3% (n=69) placebo @ 14wk*10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 31 Participants as posted 50% (n=56) vs 13.6% (n=66) placebo @ 14wk*10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 28 Participants as posted 50.8% (n=59) vs 14.5% (n=69) placebo @ 14wk*20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 30 Participants as posted 42.4% (n=59) vs 13% (n=69) placebo @ 14wk*20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted 54.2% (n=59) vs 20.3% (n=69) placebo @ 14wk*20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 32 Participants as posted 50% (n=50) vs 13.6% (n=66) placebo @ 14wk*20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 25 Participants as posted 70% (n=60) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 42 Participants as posted 56.7% (n=60) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted 60% (n=60) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 36 Participants as posted 66.7% (n=51) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 34 Participants as posted 58.1% (n=62) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 36 Participants as posted 51.6% (n=62) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted 66.1% (n=62) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 41 Participants as posted 57.1% (n=56) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 32 Participants as posted 33.3% (n=63) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted 33.3% (n=63) vs 21.9% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted 36.5% (n=63) vs 26.6% (n=64) Empagliflozin @ 14wk*10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 23 Participants as posted 33.3% (n=63) vs 23% (n=61) Empagliflozin @ 14wk*10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination · converted to % from 21 Participants as posted 29.2% (n=65) vs 14.5% (n=69) placebo @ 14wk*3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted 29.2% (n=65) vs 13% (n=69) placebo @ 14wk*3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted 33.8% (n=65) vs 20.3% (n=69) placebo @ 14wk*3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted 31.1% (n=61) vs 13.6% (n=66) placebo @ 14wk*3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · converted to % from 19 Participants as posted |
| Dropout rate | —10 mgi NCT03036150 · Phase 3 show 10 more results0.5%Dapagliflozin NCT03036150 · Phase 3 5.5%10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence 3.2%10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 17.1%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 25%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 24.2%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 5.7%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 20.7%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 9.9%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT03190694 · Phase 2 · registry result, not featured evidence | 22.9%10 mgi NCT03594110 · Phase 3 show 9 more results—Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —10 mg NCT05182840 · Phase 2 · registry result, not featured evidence —20 mg NCT05182840 · Phase 2 · registry result, not featured evidence —10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —10 mgi NCT03036150 · Phase 3 show 10 more results—Dapagliflozin NCT03036150 · Phase 3 —10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence —10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 2.9%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 8.3%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 12.1%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 0%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 3.9%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 2.2%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination —10 mg NCT03190694 · Phase 2 · registry result, not featured evidence | 7.2%10 mgi NCT03594110 · Phase 3 show 9 more results—Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence —10 mg NCT05182840 · Phase 2 · registry result, not featured evidence —20 mg NCT05182840 · Phase 2 · registry result, not featured evidence —10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination —3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 29.5%10 mgi NCT03036150 · Phase 3 show 10 more results—Dapagliflozin NCT03036150 · Phase 3 8.3%10 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence 7.9%10 mg + 2.5 mg NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 12.1%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 5.9%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 9.7%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 3%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 5.6%1.5 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 2.2%0.25 mg NCT04724837 · Phase 2 · registry result, not featured evidence · combination 1.9%10 mg NCT03190694 · Phase 2 · registry result, not featured evidence | 33%10 mgi NCT03594110 · Phase 3 show 9 more results6.4%Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence 7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 5.6%10 mg NCT05182840 · Phase 2 · registry result, not featured evidence 8.3%20 mg NCT05182840 · Phase 2 · registry result, not featured evidence 9.6%10 mg + 10 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 6.8%10 mg + 20 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 5.3%10 mg + 3 mg NCT05182840 · Phase 2 · registry result, not featured evidence · combination 4.3%3 mg NCT05182840 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mgi nasopharyngitis 4.3% (placebo 3.8%) urinary tract infection 3.6% (placebo 3.7%) hypoglycaemia 3.4% (placebo 3.3%) NCT03036150 · Phase 3 show 9 more results10 mg nasopharyngitis 6.9% (placebo 4.1%) influenza 5.5% (placebo 1.4%) NCT02547935 · Phase 2/3 · registry result, not featured evidence 10 mg + 2.5 mg nasopharyngitis 6.6% (placebo 4.1%) influenza 1.3% (placebo 1.4%) NCT02547935 · Phase 2/3 · registry result, not featured evidence · combination 10 mg hyperkalaemia 9.1% (placebo 0%) urinary tract infection 9.1% (placebo 0%) fall 6.1% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence 150 mg + 10 mg nasopharyngitis 8.8% (placebo 0%) chronic kidney disease 5.9% (placebo 0%) diarrhoea 5.9% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 50 mg + 10 mg urinary tract infection bacterial 6.5% (placebo 0%) chronic kidney disease 3.2% (placebo 0%) hyperkalaemia 3.2% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 15 mg + 10 mg chronic kidney disease 3% (placebo 0%) colitis 0% (placebo 20%) diabetes mellitus 0% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 1.5 mg brain natriuretic peptide increased 5% (placebo 0.6%) headache 4.5% (placebo 1.1%) metabolic acidosis 3.9% (placebo 1.1%) NCT04724837 · Phase 2 · registry result, not featured evidence · combination 0.25 mg headache 6.6% (placebo 1.1%) hypertension 5.5% (placebo 0.6%) metabolic acidosis 5.5% (placebo 1.1%) NCT04724837 · Phase 2 · registry result, not featured evidence · combination 10 mg any adverse event 32.1% (placebo 25%) NCT03190694 · Phase 2 · registry result, not featured evidence | show 8 more resultsnasopharyngitis 4.1% glomerular filtration rate decreased 3.8% hyperkalaemia 3.8% NCT05254002 · Phase 2 · registry result, not featured evidence hyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination 10 mg glomerular filtration rate decreased 9.9% (placebo 4.1%) hyperkalaemia 9.9% (placebo 5.5%) cortisol decreased 5.6% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence 20 mg hyperkalaemia 23.6% (placebo 5.5%) glomerular filtration rate decreased 8.3% (placebo 4.1%) upper respiratory tract infection 4.2% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence 10 mg + 10 mg hyperkalaemia 15.1% (placebo 5.5%) glomerular filtration rate decreased 11% (placebo 4.1%) hypotension 5.5% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 10 mg + 20 mg glomerular filtration rate decreased 9.5% (placebo 4.1%) hyperkalaemia 9.5% (placebo 5.5%) upper respiratory tract infection 5.4% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 10 mg + 3 mg hyperkalaemia 6.6% (placebo 5.5%) glomerular filtration rate decreased 5.3% (placebo 4.1%) cortisol decreased 2.6% (placebo 0%) NCT05182840 · Phase 2 · registry result, not featured evidence · combination 3 mg hyperkalaemia 11.4% (placebo 5.5%) cortisol decreased 4.3% (placebo 0%) upper respiratory tract infection 2.9% (placebo 2.7%) NCT05182840 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cThe assessment timepoint is not available for both results.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eAssessment timepoints differ: 12 weeks versus 14 weeks.
- fTrial phases differ: Phase 2/3 versus Phase 2.
- gPopulation context differs: registered conditions differ.
- hAssessment timepoints differ: 24 weeks versus 14 weeks.
- iPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapagliflozin
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 1 more result
show 1 more result
show 7 more results
Empagliflozin
show 2 more results
show 23 more results
Heart Failure
Shared mechanism: SGLT2 · full Heart Failure pipeline
Dapagliflozin · Farxiga / Forxiga
Marketed by AstraZeneca and partners
NCT03036124 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial measuring a hard clinical composite of death and hospitalization, and dapagliflozin significantly reduced this composite compared with placebo.
Next expected readout: December 2026 · NCT06578520 (registry estimate)
Reported efficacy
Analysis of the Hierarchical Primary Composite Endpoint (Full Analysis Set) (29 months): Primary hierarchical composite outcome (win ratio analysis, DAPA-MI): win ratio 1.34 (95% CI 1.20-1.50), P<0.001, favoring dapagliflozin over placebo; n=4017 (2019 dapagliflozin vs 1998 placebo) (met)
Result source: NCT04564742
Empagliflozin · Jardiance
Marketed by Boehringer Ingelheim and partners
NCT03057951 · Phase 3 · completed
This trial randomized patients to empagliflozin or matching placebo under double-blind conditions in a very large group, and measured a hard clinical outcome: cardiovascular death or hospitalization for heart failure. Empagliflozin significantly lowered this combined event rate compared with placebo (hazard ratio 0.79, 95% CI 0.69-0.90, p=0.0003).
Next expected readout: November 2026 · NCT05057806 (registry estimate)
Reported efficacy
Time to First Event of Adjudicated Cardiovascular (CV) Death or Adjudicated Hospitalisation for Heart Failure (HHF) (From randomization until completion of the planned treatment phase, up to 1403 days.): Primary composite endpoint (CV death or HF hospitalization) event rate: 13.8% (empagliflozin) vs 17.1% (placebo); HR 0.79, 95% CI 0.69-0.90; 21% relative risk reduction. (met)
Result source: NCT03057951
Results for Heart Failure
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Dapagliflozin | Empagliflozin |
|---|---|---|
| CV death or HF hospitalisation | 16.1% vs 20.9%−4.8 vs placeboNCT030361241 other result
| —Not posted · NCT05364190 |
| HF hospitalisation | —Not posted · NCT05676684 | 5.3% vs 4.5%+0.8 vs placeboNCT04157751 |
| CV death | 7.4% vs 8.3%−0.9 vs placeboNCT036192131 other result
| —Not posted · NCT05364190 |
| KCCQ clinical summary, change | 68.6 vs 62.8+5.8 vs placeboNCT03030235 | 4.5 vs 3.2+1.3 vs placeboNCT030579511 other result
|
CV death or HF hospitalisation
- Dapagliflozin
- 16.1% vs 20.9%−4.8 vs placeboNCT03036124
1 other result
- 9% vs 11.2% NCT04363697
- Empagliflozin
- —Not posted · NCT05364190
HF hospitalisation
- Dapagliflozin
- —Not posted · NCT05676684
- Empagliflozin
- 5.3% vs 4.5%+0.8 vs placeboNCT04157751
CV death
- Dapagliflozin
- 7.4% vs 8.3%−0.9 vs placeboNCT03619213
1 other result
- 0% vs 0% NCT04249778
- Empagliflozin
- —Not posted · NCT05364190
KCCQ clinical summary, change
- Dapagliflozin
- 68.6 vs 62.8+5.8 vs placeboNCT03030235
- Empagliflozin
- 4.5 vs 3.2+1.3 vs placeboNCT03057951
1 other result
- -1.3 vs -3.4 NCT03057977
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety
Coverage. Dapagliflozin: 8 of 8 rows · Empagliflozin: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Dapagliflozin Rows use multiple source trials | Empagliflozin Rows use multiple source trials |
|---|---|---|
| 6MWD - Change absolute change · m | 1185.76 vs 1548.23 placebo m @ 12wka,b,c NCT04249778 · Phase 4 · registry result, not featured evidence 2 other source trials262 vs 242 placebo m @ 12wk NCT03030235 · Phase 4 · registry result, not featured evidence 303.7 vs 301.3 placebo m @ 12wk NCT02653482 · Phase 4 · registry result, not featured evidence | 10 vs 5 placebo m @ 12wk10 mga,b,c NCT03448406 · Phase 3 · registry result, not featured evidence 1 other source trial13.5 vs 18 placebo m @ 12wk10 mg daily NCT03448419 · Phase 3 · registry result, not featured evidence |
| CV Death or HF Hospitalization or Urgent Visit Composite event count · % of participants | 16.3% (n=2373) vs 21.2% (n=2371) placebo*10 mgb,c,d NCT03036124 · Phase 3 · converted to % from 386 Participants as posted 4 other source trials16.4% (n=3131) vs 19.5% (n=3132) placebo*10 mg NCT03619213 · Phase 3 · converted to % from 512 Participants as posted 17.3% (n=2200) vs 20.3% (n=2172) placebo*10 mg NCT03619213 · Phase 3 · converted to % from 381 Participants as posted 10.9% (n=1218) vs 12.7% (n=1183) placebo @ 8wk* NCT04363697 · Phase 4 · registry result, not featured evidence · converted to % from 133 Participants as posted 10.4% (n=1218) vs 12.3% (n=1183) placebo @ 8wk* NCT04363697 · Phase 4 · registry result, not featured evidence · converted to % from 127 Participants as posted | 55.01% (n=265) vs 78.81% (n=265) placebo @ 18.14wk10 mgb,c,d NCT04157751 · Phase 3 · registry result, not featured evidence |
| KCCQ-TSS absolute change · score | 6.1 vs 3.3 placebo score @ 35wk10 mgb,c,e NCT03036124 · Phase 3 1 other source trial8.3 vs 5.2 placebo score @ 35wk10 mg NCT03619213 · Phase 3 | 36.19 vs 31.73 placebo score @ 12.86wk10 mgb,c,e NCT04157751 · Phase 3 · registry result, not featured evidence |
| NTproBNP 20% Reduction event count · % of participants | 32% (n=150) vs 29.3% (n=150) placebo @ 12wk*f,c NCT03030235 · Phase 4 · registry result, not featured evidence · converted to % from 48 Participants as posted 1 other source trial42.3% (n=130) vs 28.7% (n=129) placebo @ 12wk* NCT02653482 · Phase 4 · registry result, not featured evidence · converted to % from 55 Participants as posted | 33.3% (n=33) vs 6.3% (n=32) placebo @ 12wk*f,c NCT03030222 · Phase 4 · registry result, not featured evidence · converted to % from 11 Participants as posted |
| Dropout rate | 0.2%10 mgg NCT03036124 · Phase 3 show 15 more results0.3%10 mg NCT03619213 · Phase 3 0.2%10 mg NCT04564742 · Phase 3 3.4% NCT04363697 · Phase 4 · registry result, not featured evidence 70% NCT04249778 · Phase 4 · registry result, not featured evidence 9.9% NCT03030235 · Phase 4 · registry result, not featured evidence 0.8% NCT02653482 · Phase 4 · registry result, not featured evidence —Dapagliflozin + Structured Usual C NCT04298229 · Phase 3 · registry result, not featured evidence · combination 1.7%Dapagliflozin Plus Structured Usua NCT04298229 · Phase 3 · registry result, not featured evidence · combination 2%10 mg NCT03877224 · Phase 3 · registry result, not featured evidence 3.2%10mg NCT03877237 · Phase 3 · registry result, not featured evidence 17.1%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 25%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 24.2%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 5.7%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 0% NCT04730947 · Phase 2 · registry result, not featured evidence | 31.6%10 mgg NCT03057951 · Phase 3 show 12 more results25.9%10 mg NCT03057977 · Phase 3 0% NCT03030222 · Phase 4 · registry result, not featured evidence — NCT03226457 · Phase 4 · registry result, not featured evidence 21.8%10 mg NCT04509674 · Phase 3 · registry result, not featured evidence 8.4% NCT03087773 · Phase 3 · registry result, not featured evidence 21.5%10 mg NCT04157751 · Phase 3 · registry result, not featured evidence —10 mg NCT03332212 · Phase 3 · registry result, not featured evidence 0%10 mg NCT03332212 · Phase 3 · registry result, not featured evidence 5.6%10 mg NCT03332212 · Phase 3 · registry result, not featured evidence 8.3%10 mg NCT03448406 · Phase 3 · registry result, not featured evidence 10.3%10 mg daily NCT03448419 · Phase 3 · registry result, not featured evidence 2.4% NCT03200860 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —10 mgg NCT03036124 · Phase 3 show 15 more results—10 mg NCT03619213 · Phase 3 —10 mg NCT04564742 · Phase 3 — NCT04363697 · Phase 4 · registry result, not featured evidence — NCT04249778 · Phase 4 · registry result, not featured evidence — NCT03030235 · Phase 4 · registry result, not featured evidence — NCT02653482 · Phase 4 · registry result, not featured evidence —Dapagliflozin + Structured Usual C NCT04298229 · Phase 3 · registry result, not featured evidence · combination —Dapagliflozin Plus Structured Usua NCT04298229 · Phase 3 · registry result, not featured evidence · combination —10 mg NCT03877224 · Phase 3 · registry result, not featured evidence 0.6%10mg NCT03877237 · Phase 3 · registry result, not featured evidence 2.9%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 8.3%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 12.1%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 0%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination — NCT04730947 · Phase 2 · registry result, not featured evidence | 19.2%10 mgg NCT03057951 · Phase 3 show 12 more results18.3%10 mg NCT03057977 · Phase 3 — NCT03030222 · Phase 4 · registry result, not featured evidence — NCT03226457 · Phase 4 · registry result, not featured evidence 16.6%10 mg NCT04509674 · Phase 3 · registry result, not featured evidence — NCT03087773 · Phase 3 · registry result, not featured evidence 8.7%10 mg NCT04157751 · Phase 3 · registry result, not featured evidence —10 mg NCT03332212 · Phase 3 · registry result, not featured evidence 0%10 mg NCT03332212 · Phase 3 · registry result, not featured evidence 5.6%10 mg NCT03332212 · Phase 3 · registry result, not featured evidence 5.7%10 mg NCT03448406 · Phase 3 · registry result, not featured evidence 5.8%10 mg daily NCT03448419 · Phase 3 · registry result, not featured evidence — NCT03200860 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 37.8%10 mgg NCT03036124 · Phase 3 show 15 more results46.5%10 mg NCT03619213 · Phase 3 22.2%10 mg NCT04564742 · Phase 3 2% NCT04363697 · Phase 4 · registry result, not featured evidence 6% NCT04249778 · Phase 4 · registry result, not featured evidence 19.1% NCT03030235 · Phase 4 · registry result, not featured evidence 24.4% NCT02653482 · Phase 4 · registry result, not featured evidence 5%Dapagliflozin + Structured Usual C NCT04298229 · Phase 3 · registry result, not featured evidence · combination —Dapagliflozin Plus Structured Usua NCT04298229 · Phase 3 · registry result, not featured evidence · combination 10.3%10 mg NCT03877224 · Phase 3 · registry result, not featured evidence 12.2%10mg NCT03877237 · Phase 3 · registry result, not featured evidence 12.1%10 mg NCT04595370 · Phase 2 · registry result, not featured evidence 5.9%150 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 9.7%50 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 3%15 mg + 10 mg NCT04595370 · Phase 2 · registry result, not featured evidence · combination 19% NCT04730947 · Phase 2 · registry result, not featured evidence | 47.9%10 mgg NCT03057951 · Phase 3 show 12 more results41.4%10 mg NCT03057977 · Phase 3 24.2% NCT03030222 · Phase 4 · registry result, not featured evidence 8.7% NCT03226457 · Phase 4 · registry result, not featured evidence 23.7%10 mg NCT04509674 · Phase 3 · registry result, not featured evidence 13.1% NCT03087773 · Phase 3 · registry result, not featured evidence 32.3%10 mg NCT04157751 · Phase 3 · registry result, not featured evidence 2.9%10 mg NCT03332212 · Phase 3 · registry result, not featured evidence —10 mg NCT03332212 · Phase 3 · registry result, not featured evidence —10 mg NCT03332212 · Phase 3 · registry result, not featured evidence 12.7%10 mg NCT03448406 · Phase 3 · registry result, not featured evidence 13.5%10 mg daily NCT03448419 · Phase 3 · registry result, not featured evidence 20% NCT03200860 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 10 mgg hypotension 3.7% (placebo 3.1%) cardiac failure 3.2% (placebo 5.5%) nasopharyngitis 2.7% (placebo 3.2%) NCT03036124 · Phase 3 show 11 more results10 mg cardiac failure 5.7% (placebo 6.8%) urinary tract infection 3.6% (placebo 3.6%) atrial fibrillation 2.8% (placebo 2%) NCT03619213 · Phase 3 urinary tract infection 0.5% (placebo 0.2%) hypotension 0.4% (placebo 0.3%) renal impairment 0.4% (placebo 0.2%) NCT04363697 · Phase 4 · registry result, not featured evidence elective mitral valve replacement 2% (placebo 0%) gout arthritis 2% (placebo 0%) peeling dry skin 2% (placebo 0%) NCT04249778 · Phase 4 · registry result, not featured evidence volume depletion 6.2% (placebo 4.3%) urgent heart failure visit 4.9% (placebo 4.9%) back pain 0.6% (placebo 0%) NCT03030235 · Phase 4 · registry result, not featured evidence volume depletion 7.6% (placebo 5.3%) urgent heart failure visit 2.3% (placebo 5.3%) hypotension 1.5% (placebo 0.8%) NCT02653482 · Phase 4 · registry result, not featured evidence hypoglycemia 5.9% hf exacerbation 5% NCT04298229 · Phase 3 · registry result, not featured evidence · combination 10 mg hyperkalaemia 9.1% (placebo 0%) urinary tract infection 9.1% (placebo 0%) fall 6.1% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence 150 mg + 10 mg nasopharyngitis 8.8% (placebo 0%) chronic kidney disease 5.9% (placebo 0%) diarrhoea 5.9% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 50 mg + 10 mg urinary tract infection bacterial 6.5% (placebo 0%) chronic kidney disease 3.2% (placebo 0%) hyperkalaemia 3.2% (placebo 0%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination 15 mg + 10 mg chronic kidney disease 3% (placebo 0%) colitis 0% (placebo 20%) diabetes mellitus 0% (placebo 20%) NCT04595370 · Phase 2 · registry result, not featured evidence · combination dizziness or dehydration 38.1% (placebo 11.8%) worsening dyspenea 28.6% (placebo 41.2%) genitourinary infections 14.3% (placebo 5.9%) NCT04730947 · Phase 2 · registry result, not featured evidence | 10 mgg hypertension 7.1% (placebo 8.3%) hypotension 7.1% (placebo 5.9%) urinary tract infection 6.9% (placebo 5.4%) NCT03057951 · Phase 3 show 7 more results10 mg hypotension 6.4% (placebo 5.9%) hyperkalaemia 5.3% (placebo 5.9%) nasopharyngitis 4.8% (placebo 5%) NCT03057977 · Phase 3 exacerbation of heart failure 9.1% (placebo 9.4%) hypokalemia 9.1% (placebo 0%) volume depletion 9.1% (placebo 3.1%) NCT03030222 · Phase 4 · registry result, not featured evidence gout 4.3% (placebo 8.7%) NCT03226457 · Phase 4 · registry result, not featured evidence urinary tract infection 4.6% (placebo 2.9%) genital fungal infection 3% (placebo 0.8%) NCT03087773 · Phase 3 · registry result, not featured evidence 10 mg urinary tract infection 8.6% (placebo 2.8%) osteoarthritis 5.7% (placebo 0%) pruritus 5.7% (placebo 0%) NCT03332212 · Phase 3 · registry result, not featured evidence renal/urinary 37.5% (placebo 33.3%) musculoskeletal 32.5% (placebo 33.3%) cardiovascular 22.5% (placebo 43.6%) NCT03200860 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 4 versus Phase 3.
- bPopulation context differs: registered conditions differ.
- cTreatment context has not been resolved for both arms.
- dThe assessment timepoint is not available for both results.
- eAssessment timepoints differ: 35 weeks versus 12.86 weeks.
- fPopulation comparability has not been reviewed for both studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Dapagliflozin
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 4 more results
show 2 more results
+ 20 further endpoints in the CSV export.
Empagliflozin
show 13 more results
show 13 more results
show 13 more results
+ 24 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dapagliflozin's landscape · Empagliflozin's landscape